Study of SNA014 for stomach and pancreatic cancer
Part of Cancer clinical trials.
This trial tests a new drug called SNA014 for people with stomach (gastric or gastroesophageal junction) or pancreatic cancer. It aims to see if the drug is safe and works, especially for those with a specific marker called Claudin18.2.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have been diagnosed with stomach, gastroesophageal junction, or pancreatic cancer
- You are willing to sign a consent form and follow study rules
- You have had a recent scan (endoscopy, CT, MRI, or PET-CT) in the past month, if done
- You have had a biopsy or tissue test in the past year to check for Claudin18.2, if available
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new drug called SNA014 for pancreatic cancer. The drug targets a specific protein marker (Claudin-18.2) on cancer cells, and researchers want to see if it's safe and effective for patients whose tumors have this marker.
This trial uses a special PET scan to see if a new imaging agent can find a protein called claudin 18.2 on cancer cells in pancreatic, stomach, or gastroesophageal junction cancers. The scan may help doctors better see the cancer and guide treatment decisions.
This Phase 1 trial tests ASP2138 alone or with other cancer medicines in adults with stomach (including GEJ) or pancreatic cancer. You may be eligible if your tumor has a specific protein marker and your health tests and scan results meet safety requirements.
This study tests a new imaging agent that may help see certain cancers (colorectal, gastric, or pancreatic) more clearly on PET scans. It may help doctors better understand your tumor and guide treatment decisions.
This trial tests the safety and side effects of SHR-A1904, and whether it can help people with advanced stomach or pancreatic cancer. To join, your tumor must have high “Claudin 18.2” protein, and you must meet several health and timing requirements.
This trial tests a new drug called ASP546C in people with certain advanced cancers that have a specific marker (CLDN18.2). It aims to see if the drug can shrink or slow tumor growth.
Hear when a new Adenocarcinoma of the Stomach trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.